Abstract: Biomarker associated with Alzheimer's Disease (AD) and/or Mild Cognitive Impairment (MCI), where the biomarker is an intracellular or circulating microRNA and/or target protein thereof, and use thereof in methods for determining, diagnosing, monitoring AD, mild AD, moderate Ad, severe AD, MCI, early MCI, late MCI, and the like, as well as in methods for selecting candidate therapeutic compounds for treating same.

Abstract: A transgenic, non-human animal model for accelerated aging and/or age-related symptom, recombinant nucleic acid molecules, cells and methods that can be used to make such animal model and cells, methods of using the animal model and cells, to descendants of the transgenic non-human animal, obtained by breeding with the same or with another phenotype, and to a cell line or primary cell culture or to an organotypic brain slice culture, derived from the transgenic non-human animal or its descendants are disclosed.

Abstract: Biomarker associated with Alzheimer's Disease (AD) and/or Mild Cognitive Impairment (MCI), where the biomarker is an intracellular or circulating microRNA and/or target protein thereof, and use thereof in methods for determining, diagnosing, monitoring AD, mild AD, moderate Ad, severe AD, MCI, early MCI, late MCI, and the like, as well as in methods for selecting candidate therapeutic compounds for treating same.

Abstract: A transgenic, non-human animal model for accelerated aging and/or age-related symptom, recombinant nucleic acid molecules, cells and methods that can be used to make such animal model and cells, methods of using the animal model and cells, to descendants of the transgenic non-human animal, obtained by breeding with the same or with another phenotype, and to a cell line or primary cell culture or to an organotypic brain slice culture, derived from the transgenic non-human animal or its descendants are disclosed.

Abstract: Biomarker associated with Alzheimer's Disease (AD) and/or Mild Cognitive Impairment (MCI), where the biomarker is an intracellular or circulating microRNA and/or target protein thereof, and use thereof in methods for determining, diagnosing, monitoring AD, mild AD, moderate Ad, severe AD, MCI, early MCI, late MCI, and the like, as well as in methods for selecting candidate therapeutic compounds for treating same.

Abstract: An Agent Delivery System allows for targeted and controlled delivery of an agent or agents to target site, such as specific cells or a specific tissue of an individual. An exemplary Agent Delivery System includes a platform, having a silica crystal lattice base plate, coated with a collagen-containing layer. At least one agent of interest is disposed within the platform, for delivering to the target site. The agent is released when the Agent Delivery Platform is exposed to collagen-degrading compounds. Collagen-degrading compounds can be secreted by cells within a target site.

Abstract: Micro-RNA (miRNA) microarrays useful for detecting, identifying and quantitating miRNAs in a sample include oligonucleotide probes that specifically bind miRNAs. Exemplary miRNA microarray can be specific for miRNAs of human, canine, mouse, rat, or another species.

Abstract: A method of measuring cytopathic effect in cells includes providing cells in culture, using electric cell-substrate impedance sensing (ECIS) to measure the resistance of current associated with the cells, and quantifying the cytopathic effect (CPE) associated with the cells based on the measured resistance. The cells may be identified as being infected with a virus if the CPE associated with the cells is above a predetermined level. Alternatively, the cells may be provided in a healthy monolayer and infected with a virus in order to measure the effect of the virus on CPE associated with the cells. Cells may also be treated with candidate antiviral agents and the effects of the agents on the virus-infected cells may be measured to screen for and identify actual antiviral agents.

Abstract: Microarray technology allows the multiple parallel processing of information generated from matrices of huge numbers of loci on a solid substrate, which is useful in the gathering of gene signatures defining specific biological states. An approach has been developed to facilitate this process wherein genes of the same regulatory modality are selected. The transcriptional regulation of these genes is related to the same control element. Primers specific for the regulatory genes are selected, based on minimum cross-reactivity with other genes, using known gene data banks. PCR products of selected regions of known genes either binding to this sequence or whose expression is dependent on this binding, as well as genes interacting with the regulatable genes and control genes, referred to as “amplicons” or “gene cDNA fragments” of between about 450 and 1000 nucleotide bases in length, are obtained from a total RNA pool.

Abstract: Microarray technology is a fast-growing field of biomedical research, aiming to investigate changes in molecular features of hundreds of genes. The multiple parallel processing of information generated from matrices of huge numbers of loci on a solid substrate has allowed the gathering of gene signatures defining specific biological states. A new approach has been developed to facilitate this process wherein genes of the same regulatory modality are selected. The transcriptional regulation of these genes is related to the same control element, the E-box, defined by the sequence CACGTG. PCR products of selected regions of all known genes either binding to this sequence or whose expression is dependent on this binding, as well as genes interacting with E-box-binding genes and control genes, are arrayed on a nylon membrane or other appropriate microchip susbstrate, which is then used as an E-box-specific microarray.

Abstract: Microarray technology is a fast-growing field of biomedical research, aiming to investigate changes in molecular features of hundreds of genes. The multiple parallel processing of information generated from matrices of huge numbers of loci on a solid substrate has allowed the gathering of gene signatures defining specific biological states. A new approach has been developed to facilitate this process wherein genes of the same regulatory modality are selected. The transcriptional regulation of these genes is related to the same control element, the E-box, defined by the sequence CACGTG. PCR products of selected regions of all known genes either binding to this sequence or whose expression is dependent on this binding, as well as genes interacting with E-box-binding genes and control genes, are arrayed on a nylon membrane or other appropriate microchip susbstrate, which is then used as an E-box-specific microarray.

Abstract: A method for data analysis of microarrays. The method includes accessing a software program that performs a multistage analysis of the biological image, through an internet webserver. The analysis includes at least a step of comparing the digitized quantitative data for each sample. The method may further include digitizing the data for each sample and quantitating the data for each sample. Further, the method may include using a software program which quantitates the intensity and size of each sample; compares the quantitative value for each sample with the quantitative value of one or more controls; captures data, quantitates data, analyses data, or stores data; removes the background based on negative controls; averages or adjusts intensities as a function of the number of the biological images; generates reports; and stores data.

Abstract: An apparatus and a method are provided for forming a microarray of biological material on a substrate. The microarrays may consist of nucleic acids, peptides, or the like. The subject invention provides relatively simple and inexpensive machinery to produce the microarrays in a reproducible and rapid manner.

Abstract: Microarray technology is a fast-growing field of biomedical research, aiming to investigate changes in molecular features of hundreds of genes. The multiple parallel processing of information generated from matrices of huge numbers of loci on a solid substrate has allowed the gathering of gene signatures defining specific biological states. A new approach has been developed to facilitate this process wherein genes of the same regulatory modality are selected. The transcriptional regulation of these genes is related to the same control element, the E-box, defined by the sequence CACGTG. PCR products of selected regions of all known genes either binding to this sequence or whose expression is dependent on this binding, as well as genes interacting with E-box-binding genes and control genes, are arrayed on a nylon membrane or other appropriate microchip susbstrate, which is then used as an E-box-specific microarray.

Abstract: Microarray technology allows the multiple parallel processing of information generated from matrices of huge numbers of loci on a solid substrate, which is useful in the gathering of gene signatures defining specific biological states. An approach has been developed to facilitate this process wherein genes of the same regulatory modality are selected. The transcriptional regulation of these genes is related to the same control element. Primers specific for the regulatory genes are selected, based on minimum cross-reactivity with other genes, using known gene data banks. PCR products of selected regions of known genes either binding to this sequence or whose expression is dependent on this binding, as well as genes interacting with the regulatable genes and control genes, referred to as “amplicons” or “gene cDNA fragments” of between about 450 and 1000 nucleotide bases in length, are obtained from a total RNA pool.

Abstract: Apoptosis or programmed cell death is a tightly regulated mechanism used by the body to eliminate excess cells in a given tissue. If this mechanism fails, resulting in too many cells, cancer may develop in certain tissues. If the mechanism is overactive, resulting in the destruction of too many cells, tissue degeneration can occur. Therefore being able to identify which cells are destined to undergo apoptosis is critical in allowing clinicians, pathologists and researchers to develop means to detect, diagnose or treat disorders wherein the natural regulation of cell death events is interrupted. The present inventor has identified a 30 kDa protein, designated Tp30, that is specific for cells that are programmed to die. A monoclonal antibody specific for Tp30 has also been identified. The Tp30 protein and monoclonal antibodies thereto are useful in the detection and therapy of disorders wherein the natural regulation of cell death events is interrupted.